Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ECGI(.07)...Latin America distribution, Frost & Sullivan.....
ECGI(.07)...BreastCare DTS business plan update.....
I continue to hold my position in ECGI, and still expect to see prices well above the 20-cent level at some point. IMO, the 5-10 cent area looks reasonably attractive for entry/accumulation of both core and trading positions. If the company successfully executes on its current business plan, I am anticipating significant tradeable opportunities in the ECGI stock over the next 12+ months.
This week the company started putting updated business/financial presentations on the investors section of its website. It appears much of the final packaging design for the NowCardio system/product has been completed. The target time frame for the ramp-up of the BreastCare DTS business/product appears to be the first quarter of 2016. The anticipated blanket purchase orders mentioned in the business plan would represent annual revenues exceeding $20M.
Some items of interest from the May 2015 BreastCare DTS business plan.....
1)
MRDH...website items, CEO Twitter account.....
Increased my MRDH position in the last couple of weeks by picking up some shares under the 2-cent level. There has been some website activity related to MRDH in 2015, and something somewhat interesting showed up in the "portfolio" section within the last couple of days or so.
In January, CEO Anthony Dike registered another website for the ACO business. The 2015 Participating Provider list was also placed on the website in January, and it shows a significant increase in the total number of physicians operating under the MRDH ACO.......
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111235072
http://www.meho.com/mhsaco/Providerlist2015.pdf
http://www.meho.com/mhsaco/Providerlist2014.pdf
I noticed that a few weeks ago, MRDH placed a third-party health information search engine on its website.
The company does a terrible job of keeping its website completely updated/functional, so it is always difficult to determine what items on its site are still relevant. But I found it rather interesting that one of the subsidiary names that started showing up in the portfolio section of the website within the last week is "Meridian Energy Corporation", which is a name that hasn't appeared on the website in a significant number of years.
At first I thought maybe this was just nothing more than a website glitch, but the description of the subsidiary is definitely different from the past description. The current Meridian Energy is apparently focused on wireless monitoring/surveillance of energy properties and field operations. And perhaps more interesting is the fact that the document properties of the PDF file associated with this subsidiary, show that Anthony Dike created the file on May 28, 2015......
http://www.meho.com/portfolio_me.htm
http://meho.com/MeridianEnergy.pdf
Also somewhat interesting to note that the CEO opened up a Twitter account in April 2015. He has used that account primarily to advertise/promote two crowdfunding campaigns he started this year involving two technologies his privately-held cardiovascular medical device/treatment company licensed from NASA (Microwave Wound Welding, and Endothelium Preserving Microwave Treatment for Atherosclerosis).
It would probably be unlikely those campaigns would actually raise the targeted money since he does not appear to be offering equity/financial participation in the projects. Both of those technologies could have significant commercial appeal, and would represent a pretty interesting wildcard play if he were to sublicense that tech to a MRDH subsidiary or a company that MRDH might have an equity position in.
https://twitter.com/acdike1
CLCL(.01)...beverage company...China/US....
Purchased some shares of CLCL at .01 last week. CLCL is primarily involved in the manufacture/distribution of carbonated soft drinks, soft drink concentrates, juices, energy drinks, etc in China. It is also one of the lesser-known plays in the cannabis investment sector, with the company now owning both the manufacturing and distribution rights for its synthetic medical marijuana.
Press releases and information of any kind coming from the company is a fairly rare/sporadic occurrence so this obviously is a high risk play. But I'm looking for at least a double/triple from this price area at some point since there has been some relatively increased corporate activity since late 2014 or so. Also, if I recall correctly, about a year or two ago I remember seeing the company place job postings in China for 15 positions.
The slideshow/brochure presentation on the company's website features a significant amount of attention to the Kulong Energy drink which has a version for China and one for the US/International markets......
http://www.calcol.com/
The last Facebook posting (March 10) for the company mentioned that online ordering and delivery of products would be available soon.....
https://www.facebook.com/kulongenergy
Corporate Overview...clinical trials, MSC-Gro, etc....
VODG updated the "Corporate Overview" section of its website a couple of days ago. The update provides some information on the two clinical trials that VODG is planning (US-based human TBI/concussion treatment, and skeletal/muscular treatment of horses).
The recent bulk order/business from a foreign customer is mentioned. VODG also expresses interest in collaborating on additional cell-based assays for toxicology screening of drug candidates in the cardiovascular, neural and kidney markets. These new assays would use differentiated cells developed by VODG.
So there should be a number of potentially interesting developments occurring over the remainder of 2015 and into early 2016 that could lead to some sustained (or semi-sustained) price movement upward. At the very least, I think the chances are fairly good of seeing some pretty nice tradeable swings/spikes in the share price over the next 6-9 months.......
Beike Biotech...MSC-Gro testimonial.....
VODG is in the process of redesigning/updating its corporate website. Over the last day or two glimpses of the new site have started appearing online.
One thing that immediately caught my attention is one of the quotes in the "testimonials" section of the website. Apparently China-based Beike Biotech (one of the largest stem cell providers in the world) has been testing MSC-Gro. Beike is an extremely important/influential biotech company in the areas of research and clinical applications of stem cells, so when that company makes the following statement about MSC-Gro it certainly gets your eye-brow to raise a little bit.....
MSC-Gro customer order.....
WhiteNOC...ECGI financing.....
Traderfan...AHAG, suspension/revocation possibilities.....
Shuster...updated his LinkedIn profile.....
Potentially very interesting development regarding Pete Shuster.
Shuster recently updated his LinkedIn profile, and it shows his Vitro Biopharma Board of Directors position ended sometime in February/March 2015. If the profile update contains accurate information, I would assume this change to the Board of Directors probably occurred sometime within the last week or two, since VODG has not yet issued any confirmation/disclosure filing.
MRDH(.012)...2015 Physician/Provider list......
FZMD(.59)...website, strategic partnerships.....
VKIN(.30)...unusual/interesting situation developing.....
I'm still holding my full position in VKIN, and expecting to see a pretty good move in the share price possibly this year. The VKIN third quarter ended on September 30, 2014, and there has been no public update regarding its floorless convertible debt since that time. If that debt was still in existence when VKIN recently dropped down to around the 5-cent area, I would assume that a conversion request would have been put in at that time. Either the debt still exists to some extent, and/or the debt holders now own a large chunk of shares. So there is probably still some considerable risk in this investment.
However, what I find rather interesting is the fact that VKIN made private placements in the range of 20-50 cents during the months of September/October 2014. Also, it is interesting to note that last week VKIN released a PR regarding a proposed $300K private placement at 25 cents. IMO, if that placement is completed it would be a pretty clear indication from the management/investors that they think VKIN will be heading higher. Either the floorless convertible debt has been (or will be) eliminated, or there is some sort of "understanding" among all the parties involved that VKIN will be allowed to move higher and not get constantly hammered by the debt holders.
Ever since the new President/CEO (James Doris, a Canadian lawyer) was appointed on December 10, 2014, there has been a very noticeable increase in corporate activity. If I recall correctly, VKIN made a presentation at some type of investor conference several days after his appointment. Ten press releases have been issued since he took the position, subjects include VKIN's oil/energy investment, proposed large joint ventures in real estate and natural resources, etc.
http://www.dorislaw.com/?PGID=24&_n=James_A__Doris&TMID=1
AHAG(.0037)...Butler's updated biographic info.....
zenvesting...regarding FZMD.....
January 2015 executive summary.....
From the January 20, 2015 executive summary placed on the ECGI website last week.....
ECGI has partnered with Contex Canada Inc., & Ceres Technologies Inc. to design and build the new computer-controlled line that provides full automation of the processing from raw materials through final packaged product, with the capability of printing in any language. The proprietary processes and system will create significant savings in manufacturing costs.
Contex & Ceres are leaders in the Semiconductor, Nanotechnology & Biotechnology industries.
When at full production capacity the line will be capable of producing approximately 2.5 million complete pairs of BreastCare DTS™ per year with one shift and 5 million units with two shifts. Additional production lines will be added as backlog of sales demands. The phase one of the production plan will be a hand assembly production line with limited capacity to provide finished
BreastCare DTS™ devices for government registrations and samples while the full production line is built out.
Current market research indicates a retail price point in the United States for BreastCare DTS™ at $39.95. At this price, we anticipate gross margins in the 73 to 78% range. The wholesale price will be adjusted based on individual contract parameters. ECGI anticipates selling 756,000 units in Year One revenues of $18 MM with Profits of $6.6 MM; 5,449,000 units in Year Two with revenues of $116 MM with Profits of $50 MM and 13,788,000 units in Year Three with revenues of $283 MM with Profits of $154 MM based on production ramp-up and current sales discussions and projections. 75% of the sales are projected to be outside the US in Year One and 65% every year after.
BreastCare DTS™ is to be used in US physician offices during patient visits as a screening device for breast abnormalities as part of a woman’s annual examination. It is then to be used by the woman six months later if she is not in a high-risk group, and every three months if she is in a high-risk group. It is not intended to replace mammography and other detection methods, but to be used as an adjunct to other screening methods.
ECGI intends to implement sales in the US with multi-prong program that leverages several components. An ECGI sales force will target identified specific groups of physicians, some of which are considered leaders in the breast cancer segment of the medical industry. In addition to a sales force, the Company will develop an in-house sales capability for physicians interested in purchasing the product directly. A combination of the Physician’s Awareness Program, and leveraging a consumer education program with a targeted public relations and marketing campaign will be coordinated and leveraged to launch the BreastCare DTS™ device in the US. The Company also has interest from medical distribution companies for US medical and hospital distribution under consideration.
http://www.eventcardiogroup.com/about-ecgi/mission/
http://www.eventcardiogroup.com/wp-content/uploads/2014/12/Executive_Summary.pdf
Shuster...interesting statements on MSC-Gro Media......
Neuromics CEO Pete Shuster (VODG Director and primary distributor) made some interesting statements today in one of his stem cell discussion groups on LinkedIn (see below).
Apparently a large Australian company involved in stem cell expansion is (or will be) performing tests on VODG's MSC-Gro Media. I gather from Shuster's comments that the Melbourne-based company is (or will be) doing a cost/performance analysis of the VODG product versus the fetal bovine serum-based product the company currently uses.
Also, in light of today's comments by Shuster, it might be worth going back and recalling some statements VODG made in its August 12 press release. I'm not sure if those press release statements are directly related to the activity/discussions that VODG/Neuromics are having with this Australian company, or if they are completely/partially unconnected, but nonetheless it appears that VODG is experiencing or certainly expecting to see significantly increased interest in its media product(s).
From the August 12 press release.....
yowatups...Fast Track start expected in early 2015......
Perry Gooch...global ag forum (March 2015).....
The Global Forum For Innovations In Agriculture conference will be held in Abu Dhabi on March 9-10, 2015. This is a massive ag-related conference in the Middle East and attracts some pretty high-profile people.
Green Planet Group and its subsidiary (Healing The Earth) appear on the Participants List. Perry Gooch (GNPG Director and Chief Biotechnology Officer for Healing The Earth) appears on the Speakers List for this conference.......
http://www.innovationsinagriculture.com/Assets/Pages/Speaker-List
http://www.innovationsinagriculture.com/Visiting/2015-Participants-List
FZMD(.55)...debt conversion above $1......
FZMD(.80)...CEO open-market purchases.....
ECGI(.075)...certification status update.....
Jeff Liter...West Monroe Partners.....
From the November 19 CEO letter to shareholders......
2014 revenue...upcoming quarters should be interesting....
Based on the recent (November 19) CEO letter to shareholders, it looks like 2014 revenue came in at about $144K, and the fourth quarter revenue came in at about $25K. That broke what had been a nice string of revenue growth in sequential quarters and was only about a 130% increase over the previous fourth quarter.
2014 Revenues: $144K
Q1: $26K
Q2: $35K
Q3: $58K
Q4: $25K
These next couple/few quarters should be quite interesting, assuming that the revenue/profitability guidance provided by Pete Shuster in the August 12 press release is still reasonably accurate (see quote below). There has not yet been any public distancing by VODG from Shuster's statement. Although the CEO letter was issued very early in VODG's Q1 2015, I would think if the company had any doubts about meeting Shuster's guidance the CEO letter to shareholders would probably have been the most appropriate place/time to dampen expectations.
If the revenue/profitability guidance remains in place, then there should be a very noticeable surge in revenue in the first and/or second quarters (probably well over the $100K level in each quarter).
ECGI...reply to private message.....
To the person who sent me a private message regarding ECGI....
I have not sold any of my ECGI (formerly SUIP) position yet. The minimum price price range (20-40+ cents) that I mentioned in the above post still applies, and I still feel reasonably confident that I will be able to get those types of prices sometime in the next 6 months or so.
With the reverse merger now completed (November 14), there will more than likely be an increased level of IR-related activity in the coming weeks/months.
The next five trading days could be quite interesting (November 21-28) because of the floorless conversion feature of the debt arrangement entered into with Life Medical's creditors. The $376K worth of ECGI stock that will be delivered as part of the compensation for the licensing rights to BreastCare DTS, is being priced during the next 5 trading days (according to the 8-K filed on November 17).
IMO, if you do not see any sigificant or semi-permanent decline in ECGI share price during this time period, that could very well raise the eyebrows of investors and/or momentum groups monitoring the stock. It hasn't garnered much attention, but it might be worth noting that ECGI did a straight-up $100K private placement about 2 weeks ago (November 7) at about 14.3 cents per share......
Bozza LinkedIn, ECG website updates.....
Within the last several days, the Event Cardio Group website has been updated to include additions to the company's Advisory Board.....
http://www.eventcardiogroup.com/About_ECGI/Advisory_Board
Also within the last several days, Nicholas Bozza has updated his LinkedIn profile to reflect his involvement as Founder and Chief Product Officer of Event Cardio Group.
He also posted the following yesterday. I've placed a couple items of interest in bold. Bozza's use of the word "globally" in describing the launch of NowCardio in 2015 is a bit interesting to me since I was under the impression/belief the company was primarily/initially just focused on a United States (and perhaps Canada) launch in this upcoming year.....
zenvesting...reply to private message.....
Thanks for the tip on the stock you mentioned in your private message. I've actually had that stock boardmarked for quite a few years now.
Although I have never owned the stock, I've always found that company's technology quite interesting/fascinating. The relatively recent merger/acquisition activity has only made that company stronger, IMO. And without question the involvement of someone who just seems to have the "golden touch" in that particular sector is pretty hard to ignore. I think it is highly probable that stock will see higher prices.
The problem I am facing is I have too many interesting stocks I would like to buy and not enough cash. Most of my available cash at the moment is "mentally committed" to establishing some more positions in a few shells or operating companies that have perked my interest recently, and adding to my existing positions in shells and operating companies.
I picked up a few more shares in VODG this past week for trading purposes. Historically, that 5-7 cent area (give or take a penny) has been a pretty good opportunity for entry/accumulation. My guess is that I should be able to get at least a triple on those shares sometime over the next 3-4 months.
I had been planning on accumulating a few shares of LWLL in the next month or two at the ask price of 30 cents per share. The Jifro brand of hand disinfectant that LWLL manufactures/distributes is used in most Chinese hospitals, so I figured LWLL would eventually become an Ebola play. Unfortunately (according to Friday's Daily List), it looks like the common shareholders were cashed out at 88 cents. So that would have been a pretty easy almost-triple if I had just accelerated my buying plan.
SUIP(.0601)..Event Cardio Group RM approaching.....
Post RM share structure:
86.4M shares outstanding
5.5M float
$5.2M market cap
It appears likely the SUIP RM with Event Cardio Group will occur relatively soon. I'm still anticipating a significant move in the share price at some point, and still have expectations of seeing prices above the 20-cent level (see my post below from the SUIP board).
The design/performance features of the cardiac monitoring device under development appear to have pretty significant advantages over existing products.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104782326
Yesterday the company started putting up some presentations in the investor relations section of the website. The August 12, 2014 business plan document is of particular interest. At the end of that document is a milestone timeframe for the remainder of 2014 and the first half of 2015. If that timeframe turns out to be reasonably accurate, Event Cardio Group expects to make a 510k application to the FDA sometime in Q1 2015 and officially launch the product in Q2 2015.
http://client.irwebkit.com/EventCardioGroup/presentations
August 12, 2014 business plan.....
http://client.irwebkit.com/assets/uploads/presentation/889ee98ef55f37042e4cfebbf1c5856af70ba5de2fcf0d921a9539b053bc1061.pdf
ImmunoLink Therapies, StemTrophin, etc.....
1) CEO selling: For a variety of reasons, and from a retail investor perspective, CEO James Musick's decision to sell some shares of VODG probably could not have come at a worst time. General investor sentiment toward OTC-related stocks has been relatively negative over the last few weeks (at least in the majority of stocks I own/follow).
The selling will probably be viewed less troubling to current/potential VODG investors if Musick remains committed to the debt-reduction strategy outlined in the proposed deal to acquire Neuromics. Debt conversion at $1/share would be extremely favorable to the retail shareholders, but it would also be potentially very expensive to Musick on a personal financial level.
2) ImmunoLink Therapies: Things appear to be ramping up at Neuromics. Weidert Group (a design/marketing firm) registered the "Immunolinktherapies.com" website on September 25. Logo image and photos of Shuster and people from Weidert can be found in the Facebook link below. From the Neuromics Facebook page.....
Job posting...IOS Developer.....
The company placed a job posting for an IOS developer about a week ago. I've placed a few things of interest in bold.....
Diagnostic yields...significant improvements.....
I'm still anticipating that SUIP will see significantly higher share prices within the next 6-12 months or so (either in the form of a somewhat sustained move higher, or tradeable spikes). That is obviously to a large degree contingent on what things look like from any financing/debt/etc standpoint.
It appears that John Bentivoglio has hired Porter, LeVay & Rose to handle investor relations for SUIP (Event Cardio Group). IMO, that is an encouraging development.
The expected diagnostic yield numbers of Event Cardio Group's medical device could represent a significant performance improvement over current devices/technology. Nicholas Bozza appears to be pretty well-connected in the cardiac area of the medical industry, so if Now Cardio achieves the kind of performance numbers they are expecting, the product and SUIP are probably going to get a few eyebrows to raise.
From today's press release.....
Discipline of Clinical Research and Design......
VODG cells/media...Cerebral Ischemia research.....
Pete Shuster made a blog post yesterday regarding the use of Vitro Biopharma's human mesenchymal stem cells and MSC-GRO in recent Cerebral Ischemia animal research at the University of Illinois College of Medicine.
Excerpt from the blog post.....
Jeff Liter...transformational moment for VODG.....
IMO, the appointment of Jeff Liter to the Board of Directors is probably going to go down as a pretty significant transformational moment in VODG's history.
With Liter now connected with the company, I think the chances have dramatically increased that VODG will (over the next couple/few years) successfully complete some strategic merger/acquisitions and attract/complete financing(s) from institutional or corporate sources.
The wording in Liter's comment/statement in the August 20 press release is a bit interesting. I'm not sure if his comment about joining VODG's management team is meant to be taken literally or not, but clearly it appears that Liter is going to be quite active and influential in the business direction and activities surrounding VODG.....
Bozza...August 13 update on LinkedIn.....
Nicholas Bozza made an August 13 entry in the "Recommendations"
section of his LinkedIn page. Usman Ahmed is a business consultant who returned in July to work for/with Canadian Arrhythmia Institute again after spending a brief time in China working for/with Bombardier Aerospace. Based on Bozza's comments, one of the things Ahmed will be working on is business development activity related to the medical device.
Also, somewhat interesting is that Bozza mentions Canadian Arrhythmia Institute has 2 sister companies. Obviously one of these companies is Event Cardio Group, but I don't know the identity of the other company he is referencing (unless maybe that is a reference to SUIP).....
Anticipated revenue increase, MSC-Gro statement.....
From the August 12 press release....
Nicholas Bozza...appointed VP/Secretary....
According to the quarterly report, Nicholas Bozza (Canadian Arrhythmia Institute and Event Cardio Group) was appointed Vice President and Secretary of the SUIP shell on June 12. Links to Bozza's LinkedIn profile and his Twitter account are below......
db7...regarding VODG.....
breccia...RM structure, price target, etc......
MSHS(.22)...CEO/CFO LinkedIn profiles updated.....